9 Employee costs 2012 2011 2013 restated restated m m m Wages and salaries 6,262 5,846 5,312 Social security costs 685 643 641 Pension and other post-employment costs, including augmentations Note 28 170 95 414 Cost of share-based incentive plans 319 220 198 Severance and other costs from integration and restructuring activities 155 131 259 7,591 6,935 6,824 The Group provides benefits to employees, commensurate with local practice in individual countries, including, in some markets, healthcare insurance, subsidised car schemes and personal life assurance.
The charge for pension and other post-employment costs in 2013 includes a credit of 279 million following a restructuring of US post-retirement medical obligations.
The charge in 2012 includes a credit of 395 million following a change in policy relating to discretionary pension increases under certain UK pension schemes and the introduction of a limit on future pensionable pay increases in all UK schemes.
These are set out in Note 28, Pensions and other post-employment benefits.
The cost of share-based incentive plans is analysed as follows: 2013 2012 2011 m m m Share Value Plan 243 156 146 Performance Share Plan 47 45 23 Share option plans 4 11 20 Other plans 25 8 9 319 220 198 The average number of persons employed by the Group including Directors during the year was: 2013 2012 2011 Number Number Number Manufacturing 31,586 31,033 30,939 Selling, general and administration 55,660 54,803 53,826 Research and development 12,571 12,845 12,636 99,817 98,681 97,401 The average number of Group employees excludes temporary and contract staff.
The numbers of Group employees at the end of each financial year are given in the financial record on page 224.
The average number of persons employed by GlaxoSmithKline plc in 2013 was nil 2012 nil.
The compensation of the Directors and Senior Management members of the CET in aggregate, was as follows: 2013 2012 2011 m m m Wages and salaries 23 20 24 Social security costs 3 2 2 Pension and other post-employment costs 3 3 3 Cost of share-based incentive plans 13 13 11 42 38 40 GSK Annual Report 2013 149
